Please use this identifier to cite or link to this item: http://elea.unisa.it/xmlui/handle/10556/650
Title: Accelerated bone mass senescence after hematopoietic stem cell transplantation
Authors: Serio, Bianca
Pezzullo, Luca
Fontana, Raffaele
Annunziata, Silvana
Rosamilio, Rosa
Sessa, M.
Giudice, Valentina
Ferrara, Ida Lucia
Rocco, Monia
De Rosa, Gennaro
Ricci, P.
Tauchmanovà, Libuse
Montuori, Nunzia
Selleri, Carmine
Keywords: Osteoporosis;Hemopoietic stem cell transplantation;Bisphosphonates
Issue Date: 2013
Citation: Serio B, Pezzullo L, Fontana R, et al. Accelerated bone mass senescence after hematopoietic stem cell transplantation. Translational Medicine @ UniSa 2013;5(4):7-13
Abstract: Osteoporosis and avascular necrosis (AVN) are long-lasting and debilitating complications of hematopoietic stem cell transplantation (HSCT). We describe the magnitude of bone loss, AVN and impairment in osteogenic cell compartment following autologous (auto) and allogeneic (allo) HSCT, through the retrospective bone damage revaluation of 100 (50 auto- and 50 allo-HSCT) longterm survivors up to 15 years after transplant. Current treatment options for the management of these complications are also outlined. We found that auto- and allo-HSCT recipients show accelerated bone mineral loss and microarchitectural deterioration during the first years after transplant. Bone mass density (BMD) at the lumbar spine, but not at the femur neck, may improve in some patients after HSCT, suggesting more prolonged bone damage in cortical bone. Phalangeal BMD values remained low for even more years, suggesting persistent bone micro-architectural alterations after transplant. The incidence of AVN was higher in allo-HSCT recipients compared to autoHSCT recipients. Steroid treatment length, but not its cumulative dose was associated with a higher incidence of bone loss. Allo-HSCT recipients affected by chronic graft versus host disease seem to be at greater risk of continuous bone loss and AVN development. Reduced BMD and higher incidence of AVN was partly related to a reduced regenerating capacity of the normal marrow osteogenic cell compartment. Our results suggest that all patients after autoHSCT and allo-HSCT should be evaluated for their bone status and treated with anti-resorptive therapy as soonas abnormalities are detected.
URI: http://hdl.handle.net/10556/650
ISSN: 2239-9747
Appears in Collections:Translational Medicine @ UniSa. Vol.5 (jan.-apr. 2013)

Files in This Item:
File Description SizeFormat 
Serio B, Pezzullo L, Fontana R, et al. Accelerated bone mass senescence after hematopoietic stem cell transplantation.pdfarticolo di rivista472,4 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.